+

WO2005027842A8 - Associations de medicaments destinees au traitement de tumeurs - Google Patents

Associations de medicaments destinees au traitement de tumeurs

Info

Publication number
WO2005027842A8
WO2005027842A8 PCT/US2004/030368 US2004030368W WO2005027842A8 WO 2005027842 A8 WO2005027842 A8 WO 2005027842A8 US 2004030368 W US2004030368 W US 2004030368W WO 2005027842 A8 WO2005027842 A8 WO 2005027842A8
Authority
WO
WIPO (PCT)
Prior art keywords
neoplasms
drugs
combinations
treatment
patient
Prior art date
Application number
PCT/US2004/030368
Other languages
English (en)
Other versions
WO2005027842A2 (fr
WO2005027842A3 (fr
Inventor
Margaret S Lee
James M Nichols
Yanzhen Zhang
Curtis Keith
Original Assignee
Combinatorx Inc
Margaret S Lee
James M Nichols
Yanzhen Zhang
Curtis Keith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002538570A priority Critical patent/CA2538570A1/fr
Priority to MXPA06003066A priority patent/MXPA06003066A/es
Priority to EP04788798A priority patent/EP1670477A2/fr
Priority to AU2004273910A priority patent/AU2004273910A1/en
Priority to BRPI0414568-2A priority patent/BRPI0414568A/pt
Priority to JP2006527024A priority patent/JP2007505914A/ja
Application filed by Combinatorx Inc, Margaret S Lee, James M Nichols, Yanzhen Zhang, Curtis Keith filed Critical Combinatorx Inc
Publication of WO2005027842A2 publication Critical patent/WO2005027842A2/fr
Publication of WO2005027842A3 publication Critical patent/WO2005027842A3/fr
Priority to IL174232A priority patent/IL174232A0/en
Priority to NO20061325A priority patent/NO20061325L/no
Priority to IS8398A priority patent/IS8398A/is
Publication of WO2005027842A8 publication Critical patent/WO2005027842A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode permettant de traiter un patient atteint d'un cancer ou d'une tumeur, consistant à lui administrer de la chloropromazine ou un analogue de la chloropromazine et un agent antiprolifératif, simultanément ou avec un écart de 14 jours, en quantités suffisantes pour traiter le patient.
PCT/US2004/030368 2003-09-18 2004-09-16 Associations de medicaments destinees au traitement de tumeurs WO2005027842A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MXPA06003066A MXPA06003066A (es) 2003-09-18 2004-09-16 Combinaciones de farmacos para el tratamiento de neoplasmas.
EP04788798A EP1670477A2 (fr) 2003-09-18 2004-09-16 Associations de medicaments destinees au traitement de tumeurs
AU2004273910A AU2004273910A1 (en) 2003-09-18 2004-09-16 Combinations of drugs for the treatment of neoplasms
BRPI0414568-2A BRPI0414568A (pt) 2003-09-18 2004-09-16 combinações de drogas para o tratamento de neoplasmas
JP2006527024A JP2007505914A (ja) 2003-09-18 2004-09-16 新生物の治療のための薬物の併用方法
CA002538570A CA2538570A1 (fr) 2003-09-18 2004-09-16 Associations de medicaments destinees au traitement de tumeurs
IL174232A IL174232A0 (en) 2003-09-18 2006-03-09 Combinations of drugs for the treatment of neoplasms
NO20061325A NO20061325L (no) 2003-09-18 2006-03-23 Kombinasjon av legemidler for behandling av neoplasmer
IS8398A IS8398A (is) 2003-09-18 2006-04-05 Lyfjasamsetningar til að meðhöndla æxli

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50431003P 2003-09-18 2003-09-18
US60/504,310 2003-09-18

Publications (3)

Publication Number Publication Date
WO2005027842A2 WO2005027842A2 (fr) 2005-03-31
WO2005027842A3 WO2005027842A3 (fr) 2005-12-22
WO2005027842A8 true WO2005027842A8 (fr) 2006-05-18

Family

ID=34375474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/030368 WO2005027842A2 (fr) 2003-09-18 2004-09-16 Associations de medicaments destinees au traitement de tumeurs

Country Status (16)

Country Link
US (1) US20050137185A1 (fr)
EP (1) EP1670477A2 (fr)
JP (1) JP2007505914A (fr)
KR (1) KR20070012618A (fr)
CN (1) CN1878556A (fr)
AR (1) AR046163A1 (fr)
AU (1) AU2004273910A1 (fr)
BR (1) BRPI0414568A (fr)
CA (1) CA2538570A1 (fr)
IL (1) IL174232A0 (fr)
IS (1) IS8398A (fr)
MX (1) MXPA06003066A (fr)
NO (1) NO20061325L (fr)
RU (1) RU2006112834A (fr)
TW (1) TW200518752A (fr)
WO (1) WO2005027842A2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US20050154455A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US8012949B2 (en) 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
WO2007109585A2 (fr) 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Composés de biphosphonates et procédés
WO2006039721A2 (fr) 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Composes de bisphosphonate et methodes de traitement de maladies de resorption osseuse, de cancers, de douleurs osseuses, de troubles immunitaires et de maladies infectieuses
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
US8076371B2 (en) * 2006-03-09 2011-12-13 Bernstein Lawrence R Gallium compositions for the treatment of liver cancer and methods of use
US20090117203A1 (en) * 2006-03-23 2009-05-07 Tmrc Co., Ltd. Kit for cancer treatment and pharmaceutical composition for cancer treatment
EP2012801A4 (fr) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc Thérapie de combinaison de gemcitabine
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
US9205075B2 (en) 2006-07-12 2015-12-08 Mobius Therapeutics, Llc Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
US7806265B2 (en) * 2006-07-12 2010-10-05 Mobius Therapeutics, Llc Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
US9539241B2 (en) 2006-07-12 2017-01-10 Mobius Therapeutics, Llc Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
CA2670778A1 (fr) * 2006-11-28 2008-06-05 Ziopharm Oncology, Inc. Utilisation de derives d'acide indolyl-3-glyoxylique comprenant de l'indibuline, seuls ou combines a d'autres agents, pour traiter le cancer
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US8212010B2 (en) * 2008-02-25 2012-07-03 Expression Drug Designs, Llc Sphingosine 1-phosphate antagonism
JP5537000B2 (ja) 2008-08-13 2014-07-02 富士通株式会社 マルチメディア放送・同報サービス通信制御方法及び装置
WO2010086964A1 (fr) * 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 Thérapie de combinaison pour traitement d'un cancer
EP2575804A4 (fr) 2010-06-04 2013-10-23 Abraxis Bioscience Llc Procédés de traitement du cancer du pancréas
BR112013000673A2 (pt) 2010-07-12 2016-05-31 Celgene Corp formas sólidas de romidepsina e seus usos
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
WO2012079075A1 (fr) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Dérivés de phtalimide deutérés
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
CA2860862A1 (fr) * 2011-01-11 2012-07-19 Mount Sinai School Of Medicine Methodes et compositions pour le traitement du cancer et procedes associes
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
JP2014509323A (ja) * 2011-02-28 2014-04-17 マックマスター ユニヴァーシティ ドーパミン受容体遮断薬による癌の処置
CN102274238B (zh) * 2011-06-30 2012-10-03 山东弘立医学动物实验研究有限公司 一种治疗胰腺癌的药物组合物
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
EP2771014A4 (fr) * 2011-10-28 2015-07-08 Univ Nat Yang Ming Composition pharmaceutique destinée à éradiquer les cellules souches cancéreuses
WO2013130849A1 (fr) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Dérivés de phthalimide dioxopipéridinyle substitués
US8809299B2 (en) 2012-03-28 2014-08-19 Mcmaster University Combination therapy for the treatment of cancer
WO2013159026A1 (fr) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Rigosertib deutéré
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
WO2014066243A1 (fr) 2012-10-22 2014-05-01 Concert Pharmaceuticals, Inc. Formes solides de {s-3-(4-amino-1-oxo-isoindolin-2yl)(pipéridine-3,4,4,5,5-d5)-2,6-dione}
WO2014063205A1 (fr) 2012-10-26 2014-05-01 The University Of Queensland Utilisation d'inhibiteurs de l'endocytose et d'anticorps pour une thérapie anticancéreuse
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
WO2014110322A2 (fr) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Dérivés substitués de dioxopipéridinyl phtalimide
WO2015080681A1 (fr) * 2013-11-29 2015-06-04 Andac Ahmet Cenk Composés de phénothiazine-pyrimidine-2,4(1h, 3h)-dione pour le traitement du cancer
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
US20160120876A1 (en) * 2014-04-28 2016-05-05 Chi-Ying Huang Pharmaceutical composition for treatment of cancer using phenothiazine
EP3174545A1 (fr) 2014-07-28 2017-06-07 Technische Universität Dresden Inhibition efficace de hsp27
WO2016062290A1 (fr) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 Utilisations d'un médicament à base de triamtérène dans la préparation d'une composition pharmaceutique destinée au traitement du cancer
US11197865B2 (en) * 2015-06-30 2021-12-14 Shanghai Jiao Tong University Applications for promethazine in preparing anti-liver cancer and/or colon cancer and/or lung cancer products
WO2017180086A1 (fr) * 2016-04-11 2017-10-19 Pop Test Oncology Limited Liability Company Système et méthode de diagnostic et de traitement
IL292946B2 (en) 2016-03-02 2024-11-01 Eisai R&D Man Co Ltd Antibody-drug conjugates based on eribulin and methods of use
EP3439644B1 (fr) 2016-04-06 2022-01-12 Noxopharm Limited Composition d'isoflavonoïdes présentant une pharmacocinétique améliorée
WO2017173496A1 (fr) * 2016-04-06 2017-10-12 Noxopharm Limited Améliorations de la radiothérapie
KR102005887B1 (ko) * 2016-12-09 2019-07-31 서울대학교산학협력단 뇌종양의 예방 또는 치료용 약학 조성물
JP2023519990A (ja) 2020-03-30 2023-05-15 ノクソファーム リミティド 感染に関連する炎症の治療のための方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) * 1953-07-14 Phenthiazine derivatives
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6642221B1 (en) * 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
US6992082B2 (en) * 2001-01-19 2006-01-31 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
AU2003256511A1 (en) * 2002-07-11 2004-02-02 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
WO2005020913A2 (fr) * 2003-08-25 2005-03-10 Combinatorx, Incorporated Preparations, conjugues, et combinaisons de medicaments dans le traitement de neoplasmes

Also Published As

Publication number Publication date
MXPA06003066A (es) 2006-06-20
AR046163A1 (es) 2005-11-30
US20050137185A1 (en) 2005-06-23
TW200518752A (en) 2005-06-16
IL174232A0 (en) 2006-08-01
AU2004273910A1 (en) 2005-03-31
EP1670477A2 (fr) 2006-06-21
WO2005027842A2 (fr) 2005-03-31
RU2006112834A (ru) 2007-10-27
CA2538570A1 (fr) 2005-03-31
WO2005027842A3 (fr) 2005-12-22
IS8398A (is) 2006-04-05
JP2007505914A (ja) 2007-03-15
BRPI0414568A (pt) 2006-11-07
NO20061325L (no) 2006-06-06
CN1878556A (zh) 2006-12-13
KR20070012618A (ko) 2007-01-26

Similar Documents

Publication Publication Date Title
WO2005027842A8 (fr) Associations de medicaments destinees au traitement de tumeurs
WO2004006906A3 (fr) Methodes de traitement de neoplasmes
WO2004006842A3 (fr) Association de medicaments pour le traitement de tumeurs
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2005011572A3 (fr) Combinaison de medicaments pour le traitement des neoplasmes
WO2002058684A3 (fr) Combinaisons de medicaments (par exemple de chlorpromazine et de pentamidine) pour le traitement de troubles neoplasiques
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
WO2004019863A3 (fr) Therapie de combinaison pour le traitement de troubles fibrosants
WO2002056912A3 (fr) Methode de traitement du cancer
WO2001066103A3 (fr) Formulation et methode de traitement des neoplasmes par inhalation
WO2005058233A3 (fr) Methodes de traitement d'une pancreatite aigue
DE60324427D1 (de) Verfahren zur modulation der tubulindeacetylase-aktivität
WO2003030823A3 (fr) Combinaisons permettant le traitement des troubles inflammatoires
WO2003092617A3 (fr) Combinaisons destinees au traitement de troubles cutanes inflammatoires
WO2004006849A3 (fr) Combinaisons de medicaments pour le traitement de neoplasmes
WO2007134203A3 (fr) Traitements anticancéreux
WO2004007676A3 (fr) Therapie combinee servant a traiter des tumeurs
WO2004073615A3 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2005020908A3 (fr) Inhibiteurs selectifs d'activation de stat-3 et utilisations associees
WO1999056666A8 (fr) Traitement des troubles de la sexualite chez certains groupes de patients
EP1603595A4 (fr) Composition pharmaceutique pour le traitement de la pharmacodependance
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
WO2005053613A3 (fr) Combinaisons de traitement d'infections fongiques
WO2004112801A3 (fr) Polytherapie
TW200500073A (en) Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480033294.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2538570

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 174232

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004273910

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 545916

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/003066

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006527024

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004273910

Country of ref document: AU

Date of ref document: 20040916

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004273910

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067007244

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004788798

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006112834

Country of ref document: RU

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 13/2005 UNDER (72, 75) REPLACE "NICHOLS, JAMES, M." BY "NICHOLS, M., JAMES"

WWP Wipo information: published in national office

Ref document number: 2004788798

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0414568

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 1020067007244

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载